Home › Merck Statement on FDA Advisory Committee for GRASTEK (Timothy Grass Pollen Allergen Extract), Mercks Investigational Sublingual Allergy Immunotherapy Tablet
 

Keywords :   


Merck Statement on FDA Advisory Committee for GRASTEK (Timothy Grass Pollen Allergen Extract), Mercks Investigational Sublingual Allergy Immunotherapy Tablet

2013-12-13 01:17:00| Merck.com - Product News

Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today issued the following statement after the conclusion of the Allergenic Products Advisory Committee of the U.S. Food and Drug Administration (FDA) meeting to discuss GRASTEK (Timothy grass pollen allergen extract). Language: English Contact: MerckMedia:Pamela Eisele, 908-423-5042orRobert Consalvo, 908-423-6595orInvestors:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: statement committee advisory grass

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
18.06KDV Label names Gary Morrison SVP sales and marketing
18.06Potential Tropical Cyclone One Graphics
18.06Potential Tropical Cyclone One Public Advisory Number 4A
18.06Summary for Potential Tropical Cyclone One (AT1/AL012024)
18.06Atlantic Tropical Weather Outlook
18.06Eastern North Pacific Tropical Weather Outlook
18.06CCAI Recognizes 2024 Award Recipients
18.06German court dismisses anti-competitive claims against Tageos
More »